


SAPIEN 3 Ultra RESILIA valve

Excellent 1-year clinical
outcomes



Edwards

The SAPIEN 3 Ultra RESILIA valve delivers excellent 1-year outcomes in a real world study¹

Low rates of
paravalvular leak (PVL)

Outstanding
outcomes

Excellent
hemodynamics

Outstanding outcomes observed across all SAPIEN 3 Ultra RESILIA valve sizes in Transcatheter Valve Therapy (TVT) registry data.



781 sites



4,500+
matched pairs
of patients

Enhanced sealing skirt provides low rates of PVL

SAPIEN 3 Ultra RESILIA valve at 1 year



98.2%
none/trace or mild PVL

Extremely low rates at 1-year:



Mortality

7.6%



Stroke

2.7%



Aortic valve
reintervention

0.6%



Pacemaker
implantation

10.6%

Sustained quality of life improvements*



85.1

mean KCCQ score
at 1 year



30+

score improvement at
1 year vs. baseline



1 day

Median length of stay




93.3%

Discharged directly home


*Compared to SAPIEN 3 and SAPIEN 3 Ultra valves
Stinis CT et al. JACC Cardiovasc Interv. 2024; 17: 1032–44

Excellent hemodynamics

Significantly lower echo-measured gradients sustained at 1 year^{*†}




Larger EOA measurements across all valve sizes^{*}



^{*}Compared to SAPIEN 3 and SAPIEN 3 Ultra valves. Data collected at discharge. P Value <0.0001

The only transcatheter valve featuring RESILIA anti-calcification tissue technology²



Potential to improve valve longevity and reduce risk of reintervention²

A significant reduction in calcium accumulation compared to other tissue technologies^{*†}

The only approved THV with dry tissue storage

Same tissue technology as the #1 implanted surgical valve in the world^{*}

^{*} RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg. 2015;149:340-345.

[†] No clinical data are available to evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.

Every indicated patient benefits from comprehensive lifetime management

SAPIEN 3 Ultra RESILIA valve: the leading solution for lifetime management

Life

The lowest rate of death and disabling stroke in any pivotal TAVR trial³

Time

The highest rate of TAVR survival in any pivotal trial⁴

Management

Optimally designed to keep future options possible



Explore the technology at
heartvalves.com/gb

References:

1. Kini A, et al. 1-year real-world outcomes of TAVR with fifth-generation balloon-expandable valve in the United States. JACC Cardiovasc Interv. 2024; S1936-8798(24)01711-4
2. Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149:340-5.
3. Mack M.J., et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New Eng Journal of Med. 2019;380:1695-705.
4. Mack M.J., et al. Transcatheter aortic-valve replacement in low-risk patients at five years. New Eng Journal of Med.2023;389:1949-60.

No clinical data is available to evaluate the long-term clinical impact or RESILIA technology in patients. Additional data for up to 10 years of follow-up is being collected to monitor the long-term safety and performance of the RESILIA tissue technology. Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, RESILIA, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2025 Edwards Lifesciences Corporation. All rights reserved. PP--EU-10157 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards